We are looking for high-value, truly differentiating first or best-in-class treatments in:
Focus on areas of high unmet need, build on strong mid/late-stage pipeline
Atherosclerosis
- ASCVD prevention and treatment
- Novel mechanisms beyond LDL-C, Lp(a), HTN, and inflammation.
Heart Failure/Atrial Fibrillation
- Heart Failure with reduced or preserved ejection fraction
- Safer anti-arrhythmic therapies for Afib
- Cardiomyopathies, thrombosis, and hypertension
Metabolism/Obesity
- Novel mechanisms that complement SoC
- Better tolerability and weight loss maintenance
Nephrology
- Chronic Kidney Disease (Stage 3b/4)
- Glomerular diseases e.g. IgA Nephropathy (IgAN), Alport Syndrome
Avi Spier
Strong foundation and expect 6 Ph3 readouts, >10 Ph2 readouts in next 5 years Dermatology
- Atopic Dermatitis
- Chronic Spontaneous Urticaria (CSU)
- Hidradenitis Suppurativa
- Lichen Planus
- Vitiligo
Rheumatology
- Lupus nephritis (LN)
- Sjogren's disease
- Spondyloarthropathies
Systemic Lupus Erythematosus (SLE)
Inflammatory Bowel Disease
- Crohn's Disease
- Ulcerative Colitis
Exploratory Areas
- B cell reset
- Food allergy
- Rheumatoid Arthritis
Dominic Ehrismann
Focus on multiple sclerosis, neuromuscular and neurodegenerative diseases
Neurodegeneration
- Parkinson’s Disease (PD)
- Alzheimer’s Disease
- Huntington’s Disease
Neuromuscular
- Amyotrophic lateral sclerosis (ALS)
- Larger neuro-muscular indications
Multiple Sclerosis & Immuno-Neurology
- Multiple Sclerosis (MS)
- Other neuroimmunology diseases (e.g., CIDP & MG)
Christopher Adams
Focus areas on solid tumors, RLT and hematology
Solid Tumors
- Breast cancers
- Prostate cancers
- Lung cancers
- Colorectal and pancreatic cancers
Radioligand Therapy
- Identify RLTs or PET imaging agents in solid tumor indications including novel isotopes, chelators, vectors, and targets
Hematology
- Non-Hodgkin lymphoma (NHL)
- Acute myeloid leukemia (AML) / Myelodysplastic syndrome (MDS)
- Non-malignant hematology, Myeloproliferative Neoplasms (MPN)
